Aller au contenuAller au menuAller à la recherche

Parkinson's Disease Symposium

Du 4 septembre 2013 au 5 septembre 2013

The objective of this meeting is to brainstorm and dialogue between international Parkinson’s disease experts and representatives of leading healthcare companies and innovative biotech startups, to better understand the evolution of the therapeutic area (met versus unmet needs, clinical trial design, derisking translational development, emerging treatment challenges) and its strategic implications for the Healthcare industry.

The topics cover the most striking unmet treatment needs of our patients with the ambition to provide a cure for Parkinson’s disease in the future. Each expert will give an interactive presentation where he will briefly review his topic, define meaningful surrogate markers for the design of future clinical trials and identify the most promising and innovative treatment avenues.

September 4,

2013 MORNING SESSION (9:00-12:10) 

Preclinical models of PD (caveats of current models, tran- slational potential and the place of new models) Chairmen: M. Vila, Barcelona, Spain and S. Hunot, Paris, France

9:00-9:40 Mechanisms of cellular death in PD S. Przedborski, New York, USA

9:40-10:20 New animal models of PD E. Bezard, Bordeaux, France

10:20-10:50 Coffee Break

10:50-12:10 Progress in pathophysiology, pathogenesis and genetics of PD Chairmen: P. Burbaud and E. Bezard, Bordeaux, France

10:50-11:30 The contribution of genetics to the identification of new treatment targets A. Singleton, Bethesda, USA

11:30-12:10 Alpha-synuclein – what makes the origami bird un fold? G. Petsko, Waltham, USA

12:10-13:30 Lunch Break

13:30-14:50 Unmet needs and emerging treatment challenges in PD Chairmen: F. Tison, Bordeaux, France and J. Obeso, Pamplona, Spain

13:30-14:10 Motor and non-motor signs D. Burn, Newcastle, UK

14:10-14:50 Disease modification and neuroprotection W. Olanow, New York, USA

14:50-15:20 Coffee Break 15:20-16:40 Biomarkers Chairmen: W. Meissner, Bordeaux, France and G. Petsko, Waltham, USA

15:20-16:00 CSF and plasma: will we succeed? J. Zhang, Seattle, USA

16:00-16:40 Imaging biomarkers: red herring or real possibilities? N. Pavese, London, UK

September 5,

2013 MORNING SESSION (9:00-12:45)

9:00-11:00 New design for clinical trials Chairmen: O. Rascol, Toulouse, France and J. Ferreira, Lisbon, Portugal

9:00-9:40 Continuous modeling of clinical outcomes J. Gobburu, Baltimore, USA 9:40-10:20 Adaptive trial design. V. Dragalin, Cambridge, USA

10:20-11:00 Regulatory authorities: views of the European Medicines Agency P. Balabanov, London, UK

11:00-11:25 Coffee Break

Critical issues for the success of clinical trials. Chairmen: D. Devos, Lille, France and M.C. Rodriguez-Oroz, San Sebastian, Spain

11:25-12:05 The interest of well-defined cohorts for clinical POC studies W. Meissner, Bordeaux, France

12:05-12:45 How to improve study enrollment? J.C. Corvol, Paris, France

12:45-14:00 Lunch Break


14:00-15:20 The industry perspective Chairman: E. Bezard, Bordeaux, France

14:00-14:40 Scientific issues and challenges K. Merchant, Indianapolis,USA 14:40-15:20 Economic strategy and decision making T. Blackburn, Hoboken, USA

15:20-15:50 Funding of clinical trials – convergence of industry, academia and patient advocacy groups S. Chowdhury, Michael J. Fox Foundation, New York, USA

15:50-16:20 Innovation forecasting through bibliometrics, patent landscaping and market analysis P. Gorry, Bordeaux, France

16:20-16:50 FAREWEL

Registration fees
Regular academic attendees 200 euros
Industrial 500 euros
Contact and registration


Céline Vega Roïatti (symposium2013 @
Dernière mise à jour le 26.08.2013